Zacks: Biopharmx Corp (NASDAQ:BPMX) Given Consensus Rating of “Strong Buy” by Brokerages
Shares of Biopharmx Corp (NASDAQ:BPMX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price objective of $3.38 for the company and are predicting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Biopharmx Corp an industry rank of 108 out of 265 based on the ratings given to its competitors.
A number of equities analysts have issued reports on BPMX shares. Roth Capital set a $3.00 target price on Biopharmx Corp and gave the stock a “buy” rating in a report on Thursday, May 4th. Maxim Group reaffirmed a “buy” rating and issued a $3.00 target price on shares of Biopharmx Corp in a report on Thursday, May 4th. Finally, HC Wainwright set a $3.00 target price on Biopharmx Corp and gave the stock a “buy” rating in a report on Thursday, May 4th.
TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/07/zacks-biopharmx-corp-nasdaqbpmx-given-consensus-rating-of-strong-buy-by-brokerages.html.
In related news, major shareholder Franklin Resources Inc purchased 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was bought at an average price of $0.34 per share, with a total value of $85,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
An institutional investor recently raised its position in Biopharmx Corp stock. Vivo Capital LLC increased its stake in shares of Biopharmx Corp (NASDAQ:BPMX) by 10.0% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 14,096,338 shares of the company’s stock after buying an additional 1,282,052 shares during the period. Biopharmx Corp makes up about 1.7% of Vivo Capital LLC’s portfolio, making the stock its 13th largest position. Vivo Capital LLC owned approximately 19.02% of Biopharmx Corp worth $6,752,000 at the end of the most recent quarter.
Shares of Biopharmx Corp (BPMX) traded down 2.7667% during mid-day trading on Monday, reaching $0.2917. The company had a trading volume of 888,374 shares. The firm’s 50-day moving average price is $0.44 and its 200 day moving average price is $0.51. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $1.22. The company’s market cap is $21.62 million.
Biopharmx Corp (NASDAQ:BPMX) last issued its earnings results on Tuesday, June 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. Equities analysts expect that Biopharmx Corp will post ($0.31) EPS for the current year.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.